Radiotheranostics Market Size & Growth Forecast 2026–2035, By Segments (Approach, Radioisotope, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Radiotheranostics Market size stood at USD 10.44 Billion in 2025 and is predicted to grow at a 13.3% CAGR from 2026 to 2035, surpassing USD 36.39 Billion by 2035. The industry revenue for 2026 is estimated at USD 11.68 billion.
Get more details on this report
Request Free Sample ReportRadiotheranostics Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 54.23% share in 2025, supported by advanced nuclear medicine infrastructure, established clinical workflows, and strong industry participation driving adoption and commercialization.
- Europe is projected to grow at a 14.9% CAGR as precision oncology adoption increases and hospitals expand the use of integrated molecular imaging and targeted therapeutic workflows.
Segment Momentum
- Targeted Therapeutic held a 64.43% share in 2025 because it combines molecular targeting with treatment delivery, supporting precise, patient-specific care and expanding use within established clinical workflows.
- 18F with Y-90 is growing fastest because it supports an integrated imaging-to-therapy pathway, helping clinicians improve treatment planning and advance precision-focused radiotheranostic workflows.
Market Expansion Drivers
- Integration of molecular imaging with targeted radionuclide therapy enabling precision oncology treatment selection.
- Expanding clinical validation and regulatory approvals accelerating radiopharmaceutical adoption in oncology centers.
- AI-enabled dosimetry and imaging analytics improving personalized radiotheranostic treatment planning efficiency.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Top players in the radiotheranostics market include Novartis AG (Switzerland), Bayer AG (Germany), Lantheus Holdings, Inc. (United States), Telix Pharmaceuticals Limited (Australia), POINT Biopharma Global Inc. (United States), Fusion Pharmaceuticals Inc. (Canada), Actinium Pharmaceuticals, Inc. (United States), RadioMedix, Inc. (United States), SHINE Technologies, LLC (United States), NorthStar Medical Radioisotopes, LLC (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
The integration of diagnostic imaging and therapeutic radionuclides is shaping purchasing and treatment decisions in the radiotheranostics market by allowing oncology teams to identify suitable patients before therapy is initiated. Molecular imaging reveals target expression, lesion distribution, and disease burden with a level of specificity that supports therapy selection based on biological suitability rather than broad tumor classification alone. This connection between imaging and treatment is increasing demand for the radiotheranostics market because it makes radiopharmaceutical use more actionable in routine oncology practice, strengthens physician confidence in patient stratification, and encourages investment in coordinated imaging-therapy workflows at centers seeking more precise cancer treatment pathways.
Expanding clinical validation and regulatory approvals accelerating radiopharmaceutical adoption in oncology centers
As clinical evidence becomes more established and more products receive regulatory clearance, the radiotheranostics market benefits from a clearer path from specialist use to broader institutional adoption. Oncology centers are more willing to commit to radiopharmaceutical programs when published outcomes, safety data, and approved indications reduce uncertainty around treatment protocols, reimbursement discussions, and multidisciplinary care integration. This expanding validation is supporting market expansion by lowering the barriers that often delay hospital procurement, physician referral behavior, and infrastructure planning, especially where nuclear medicine capabilities must be aligned with oncology service lines.
AI-enabled dosimetry and imaging analytics improving personalized radiotheranostic treatment planning efficiency
AI-enabled dosimetry and imaging analytics are influencing market adoption by making personalized treatment planning more operationally feasible for providers managing complex radiotheranostic workflows. In the radiotheranostics market, therapy planning often depends on interpreting imaging data, estimating radiation dose distribution, and adjusting treatment decisions to individual patient characteristics, tasks that can be time-intensive and dependent on highly specialized expertise. AI tools help standardize image analysis and dose estimation, which improves consistency in clinical decision-making and allows centers to handle greater case volume without proportionally increasing planning burden, contributing to market size growth as precision treatment becomes easier to implement in everyday oncology practice.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Integration of molecular imaging with targeted radionuclide therapy enabling precision oncology treatment selection | 2.50% | High | North America, Europe | Medium | Mid Term |
| Expanding clinical validation and regulatory approvals accelerating radiopharmaceutical adoption in oncology centers | 2.20% | High | North America, Europe | Medium | Near Term |
| AI-enabled dosimetry and imaging analytics improving personalized radiotheranostic treatment planning efficiency | 1.80% | Moderate | North America, Europe | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the leading position in the radiotheranostics market in 2025, accounting for a 54.23% share. This leadership is backed by the region’s established nuclear medicine infrastructure, broad access to advanced diagnostic and therapeutic workflows, and the presence of major industry participants actively supporting product development and clinical adoption. In practice, these advantages help providers move radiotheranostic agents more efficiently from specialized imaging into targeted treatment pathways, supporting higher procedure volumes and stronger commercial uptake across the region.
Europe is projected to expand at a 14.9% CAGR over the forecast period in the radiotheranostics market, driven by accelerating adoption of precision oncology approaches and growing integration of theranostic protocols into hospital-based nuclear medicine practice. Growth is being aided by the region’s increasing emphasis on targeted cancer care, which is translating into wider use of molecular imaging to guide therapy selection and monitor response. As more treatment centers incorporate these workflows into routine oncology management, demand is rising across both diagnostic and therapeutic applications.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Oncology IntegrationGermany is advancing radiotheranostics through established nuclear medicine expertise and coordinated hospital networks. Organizations in Germany emphasize standardized clinical workflows, reliable isotope availability, and expanded access to personalized oncology treatments.
France 🇫🇷
Nuclear Medicine ExpansionFrance continues integrating radiotheranostics into comprehensive cancer treatment programs through specialized nuclear medicine facilities. Healthcare organizations in France focus on clinical collaboration, radiopharmaceutical access, and optimized patient selection for targeted therapies.
Italy 🇮🇹
Specialized Care NetworksItaly is expanding radiotheranostics through specialized oncology and nuclear medicine centers that support personalized treatment pathways. Institutions across Italy prioritize clinician expertise, coordinated diagnostics, and improved infrastructure for targeted radiopharmaceutical therapies.
Japan 🇯🇵
Advanced Imaging AdoptionJapan integrates radiotheranostics with sophisticated diagnostic imaging capabilities to improve treatment planning and patient management. Healthcare institutions in Japan prioritize high-quality imaging infrastructure, regulatory compliance, and precision-based therapeutic applications.
South Korea 🇰🇷
Isotope Production FocusSouth Korea is strengthening radiotheranostics by expanding domestic radiopharmaceutical production and specialized oncology services. Medical providers in South Korea invest in modern imaging systems and collaborative clinical programs to support personalized cancer treatment approaches.
United States 🇺🇸
Clinical Translation HubThe U.S. radiotheranostics market is supported by expanding clinical research, specialized treatment centers, and investments in targeted radiopharmaceutical development. Healthcare providers across the U.S. continue strengthening isotope supply, imaging integration, and multidisciplinary cancer care pathways.
Segment Leadership and Growth Trends
Radiotheranostics Market Share (%), Approach, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTargeted Therapeutic held a 64.43% share of the radiotheranostics market in 2025, reflecting its central role in linking molecular targeting with treatment delivery in a clinically actionable framework. Its leadership is underpinned by the practical value of combining patient-specific targeting with therapeutic intent, which aligns well with how radiotheranostics is used to identify, treat, and monitor disease through the same biological pathway. The same treatment-focused utility is also driving continued expansion, as demand builds around approaches that can move beyond diagnosis alone and support more precise intervention within established care pathways in the radiotheranostics market.
Radioisotope Segment Analysis: Lutetium-177 (Largest Segment) vs 18F with Y-90 (Fastest-Growing Segment)
Within the radiotheranostics market, Lutetium-177 accounted for a 37.76% share in 2025, making it the leading radioisotope segment. Its market leadership is backed by its established fit within theranostic workflows, where isotopes must function reliably within targeted treatment models rather than serve a purely diagnostic role. This practical compatibility with treatment-oriented applications helps sustain Lutetium-177 demand, especially in settings where radiotheranostics adoption depends on isotopes that integrate effectively into existing clinical and operational use patterns.
18F with Y-90 is emerging as the fastest-growing radioisotope segment in the radiotheranostics market because it supports a more connected diagnostic-to-therapy pathway than single-purpose isotope choices. Growth momentum is tied to the increasing preference for combinations that align imaging and therapeutic planning more closely, improving how clinicians evaluate targets and proceed toward treatment. Relative to alternatives that are more narrowly positioned, 18F with Y-90 benefits from this integrated use case, which is becoming more relevant as radiotheranostics applications expand toward more coordinated and precision-driven care models.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Approach | Targeted Therapeutic, Targeted Diagnostic | Targeted Therapeutic | Targeted Therapeutic |
| Radioisotope | Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, Others | Lutetium-177 | 18F with Y-90 |
| Application | Oncology, Non-oncology | Oncology | Oncology |
Competitive Landscape and Market Positioning
1. Novartis AG (Switzerland)
2. Bayer AG (Germany)
3. Lantheus Holdings Inc. (United States)
4. Telix Pharmaceuticals Limited (Australia)
5. POINT Biopharma Global Inc. (United States)
6. Fusion Pharmaceuticals Inc. (Canada)
7. Actinium Pharmaceuticals Inc. (United States)
8. RadioMedix Inc. (United States)
9. SHINE Technologies LLC (United States)
10. NorthStar Medical Radioisotopes LLC (United States)
Advancements in targeted diagnostic and therapeutic integration are accelerating development in the radiotheranostics market. Strong research pipelines are enabling precision-focused treatment approaches that combine imaging and therapy capabilities. Collaborative research efforts are supporting faster clinical translation of emerging solutions. New therapeutic introductions are increasingly centered on improving treatment specificity and patient outcome optimization.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| NUCLIDIUM | Mar-26 | NUCLIDIUM completed a CHF 26.4 million Series B extension, bringing total Series B funding to CHF 105 million. The capital is allocated to advance clinical development of its NU101 and NU201 radiotheranostic programs targeting metastatic castration-resistant prostate cancer and metastatic breast cancer, reinforcing its position in targeted nuclear medicine oncology pipelines and accelerating late-stage translational development. |
| Sarvodaya Healthcare; Oncidium Foundation | Mar-26 | Sarvodaya Healthcare partnered with the Oncidium Foundation to introduce radiotheranostics-based nuclear therapy services for cancer treatment. The collaboration focuses on implementing precision-guided radiotheranostic approaches to improve treatment personalization and clinical outcomes, expanding access to targeted nuclear medicine therapies within oncology care delivery systems. |
| Actinium Pharmaceuticals | Mar-25 | Actinium Pharmaceuticals advanced development of its ATNM-400 Actinium-225 antibody radioconjugate, demonstrating strong preclinical efficacy across multiple solid tumor models. The progress strengthens the company’s targeted alpha-emitter platform strategy and supports expansion of its radiotheranostic pipeline with potential broad oncology applicability across solid tumor indications. |
| SHINE Technologies | Oct-24 | SHINE Technologies advanced isotope production and collaborative preclinical capabilities supporting radiotheranostics development. The initiative strengthens its role as a critical upstream supplier of medical isotopes, enhancing reliability of supply chains for diagnostic and therapeutic nuclear medicine applications and enabling downstream innovation across radiotheranostic pipelines. |
| Telix Pharmaceuticals Limited | Jul-24 | Telix Pharmaceuticals progressed late-stage development and global rollout of PSMA-targeted imaging agents while advancing therapeutic candidates aligned with radiotheranostic care pathways. The company emphasized diagnostics-led commercialization strategies, positioning imaging agents as clinical entry points to support broader adoption of integrated diagnostic-therapeutic nuclear medicine platforms. |
| Sanofi; Orano Med | Oct-24 | Sanofi partnered with Orano Med to advance next-generation radioligand therapies for rare cancers. The collaboration combines oncology and targeted alpha therapy expertise to accelerate development of radiotheranostic treatment approaches, supporting pipeline expansion in precision nuclear medicine for difficult-to-treat cancer indications. |
| Lantheus | Jun-24 | Lantheus acquired global rights to 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 radiopharmaceutical pairs from Life Molecular Imaging. The acquisition strengthens its radiotheranostics portfolio by integrating complementary diagnostic and therapeutic agents targeting prostate and breast cancer, enhancing its position in clinically advanced radiotheranostic development. |
| Ariceum Therapeutics | Jan-24 | Ariceum Therapeutics submitted an application to the UK MHRA to initiate a Phase 1 clinical trial of 123I-ATT001 in recurrent glioblastoma. The development advances early-stage radiotheranostic evaluation in central nervous system oncology, expanding the application scope of targeted radiopharmaceutical therapies in aggressive tumor indications. |
| Telix Pharmaceuticals Limited; Merck KGaA | Jul-23 | Telix Pharmaceuticals initiated a Phase I trial of TLX250 in combination with Merck KGaA’s peposertib for patients with solid tumors. The study evaluates combination therapy integrating targeted radiation with DNA damage response inhibition, advancing clinical exploration of synergistic radiotheranostic and oncology treatment approaches. |
| Novartis AG | Dec-22 | Novartis AG received European Commission approval for Pluvicto (lutetium Lu-177 vipivotide tetraxetan) combined with androgen deprivation therapy for metastatic castration-resistant prostate cancer. The approval establishes regulatory validation for radioligand therapy in advanced prostate cancer, reinforcing commercialization of targeted radiotheranostic treatment pathways in Europe. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Radiotheranostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Radiotheranostics Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow large is the radiotheranostics market?
What is the expected industry size of radiotheranostics by 2035?
How is the integration of diagnostic imaging and targeted therapy influencing adoption in radiotheranostics?
What role is regulatory progress and clinical validation playing in expanding radiotheranostics uptake?
Why does the targeted therapeutic approach lead the radiotheranostics market?
Why is 18F with Y-90 the fastest-growing radioisotope segment in the radiotheranostics market?
Why does North America dominate the radiotheranostics market?
What is fueling radiotheranostics market growth in Europe?
Who holds a significant market share in the radiotheranostics landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization